EUVIMEDEUVIMED entdecken
Crossref

Anlotinib Inhibits Ovarian Cancer and Enhances Cisplatinum Sensitivity via Suppressing NOTCH2 Expression and Stemness

Xiaosheng Xu, Qun Wang, Lifei Shen, Yuhong Shen, Hua Liu, Yan Liu, Zhijian Yang, Robert M Hoffman, Weiwei Feng

Anticancer Research · 2024-04 · 44 (4) · 1399-1407

DOI: 10.21873/anticanres.16936 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, online erschienen am 27.03.2024. Verfasst von Xiaosheng Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, P.R. China. Hauptthemen laut MEDLINE: Indoles, Ovarian Neoplasms, Quinolines. Die Arbeit wurde bisher 7-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: The prognosis of ovarian cancer (OC) patients is especially poor for patients with chemotherapy resistance. Anlotinib, a novel multi-targeted tyrosine kinase inhibitor, has shown encouraging clinical efficacy in several tumor types. The aim of the present study was to examine the inhibitory efficacy and mechanism of anlotinib on the proliferation and chemosensitivity of OC cells. MATERIALS AND METHODS: The inhibitory effects of Anlotinib on SKOV3 and OVCAR3 OC cells were examined using CCK-8 cell-viability, colony-formation, flow-cytometry, transwell-migration and sphere-formation assays. A xenograft mouse model was used for in vivo studies. RT-qPCR and western blotting were used to detect gene expression. RESULTS: Molecular targets of anlotinib were elevated in OC patient tumors. Anlotinib significantly inhibited ovarian cancer cell proliferation and migration in vitro. Anlotinib enhanced the sensitivity of ovarian cancer cells to cisplatinum both in vitro and in vivo. Anlotinib suppressed sphere formation and the stemness phenotype of OC cells by inhibiting NOTCH2 expression. CONCLUSION: Anlotinib inhibits ovarian cancer and enhances cisplatinum sensitivity, suggesting its future clinical promise.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesOvarian NeoplasmsQuinolinesAnimalsFemaleHumansMiceApoptosisCell Line, TumorCell ProliferationCisplatinReceptor, Notch2Signal Transduction

Stichwörter der Autor:innen

AnlotinibNOTCH2cancer cell stemnesschemosensitivitycisplatinum ovarian cancer

Substanzen

anlotinibCisplatinIndolesNOTCH2 protein, humanQuinolinesReceptor, Notch2

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, P.R. China.
  • AntiCancer, Inc., San Diego, CA, U.S.A.
  • Department of Surgery, UCSD, San Diego, CA, U.S.A.
  • Department of Obstetrics and Gynecology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, P.R. China; fww12066@rjh.com.cn.

Zitieren

APA

Xu, X., Wang, Q., Shen, L., Shen, Y., Liu, H., Liu, Y., Yang, Z., Hoffman, R. M., & Feng, W. (2024). Anlotinib Inhibits Ovarian Cancer and Enhances Cisplatinum Sensitivity via Suppressing NOTCH2 Expression and Stemness. Anticancer Research, 44(4), 1399-1407. https://doi.org/10.21873/anticanres.16936

Vancouver

Xu X, Wang Q, Shen L, Shen Y, Liu H, Liu Y, et al. Anlotinib Inhibits Ovarian Cancer and Enhances Cisplatinum Sensitivity via Suppressing NOTCH2 Expression and Stemness. Anticancer Research. 2024;44(4):1399-1407. doi:10.21873/anticanres.16936

BibTeX
@article{Xu2024,
  author = {Xu, Xiaosheng and Wang, Qun and Shen, Lifei and Shen, Yuhong and Liu, Hua and Liu, Yan and Yang, Zhijian and Hoffman, Robert M and Feng, Weiwei},
  title = {Anlotinib Inhibits Ovarian Cancer and Enhances Cisplatinum Sensitivity via Suppressing NOTCH2 Expression and Stemness},
  journal = {Anticancer Research},
  year = {2024},
  volume = {44},
  number = {4},
  pages = {1399--1407},
  doi = {10.21873/anticanres.16936}
}
Kostenlos starten →